3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Neuroblastoma
7
Lymphoma, B-Cell
5
Lymphoma
5
Rhabdoid Tumor
3
Neoplasms
3
Medulloblastoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms, Germ Cell and Embryonal
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Ganglioneuroblastoma
2
Ependymoma
2
Enteropathy-Associated T-Cell Lymphoma
2
Brain Neoplasms
2
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Interventions
Injections
6
pembrolizumab
5
toripalimab
3
tislelizumab
3
senaparib
3
Bevacizumab
3
sintilimab
2
Technetium
2
Specimen Handling
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Carboplatin
2
Blood Specimen Collection
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
tazemetostat
1
spartalizumab
1
sacituzumab govitecan
1
rucaparib
1
osimertinib
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
cemiplimab
1
cedazuridine
1
atezolizumab
1
WW Domain-Containing Oxidoreductase
1
Ultrasonography, Doppler
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
etoposide phosphate
×
1 year
×
Clear all
NCT04469530
2026-02-27
AflacST1903
Emory University
Phase 2
Recruiting
55 enrolled